New York, New York, August 20, 2026 — A chemotherapy-free combination of four targeted treatments has produced encouraging and durable results in people with hormone receptor-positive, HER2-positive metastatic breast cancer, according to researchers at the Icahn School of Medicine at Mount Sinai. Findings from the multicenter phase 1/2 ASPIRE clinical trial suggest that combining hormone-blocking therapy with medicines directed at two major cancer-growth pathways may offer a viable first-line strategy for selected patients. The approach uses anastrozole, palbociclib, trastuzumab, and pertuzumab, bringing together endocrine therapy, cell-cycle inhibition, and dual HER2 blockade. Although the early-stage study was small and was not designed to replace current standards of care, investigators say its results raise the possibility that some patients could begin treatment without conventional chemotherapy, potentially reducing treatment-related toxicity and preserving quality of life.
Hormone receptor-positive, HER2-positive breast cancer represents a biologically complex subgroup of the disease. Tumor cells in these cancers depend partly on estrogen or other hormonal signals and also carry excessive amounts of human epidermal growth factor receptor 2, or HER2, a protein that stimulates proliferation and survival. These overlapping drivers can make treatment more complicated, but they also create multiple therapeutic targets. Anastrozole suppresses the production of estrogen, thereby limiting hormonal stimulation of cancer cells. Trastuzumab and pertuzumab bind to HER2 through distinct mechanisms, disrupting receptor signaling and helping the immune system identify malignant cells. Palbociclib inhibits cyclin-dependent kinases 4 and 6, proteins that regulate progression through the cell cycle. By blocking these enzymes, the drug can prevent tumor cells from advancing from the growth phase into DNA replication and division.
The ASPIRE trial enrolled patients with previously untreated HR-positive, HER2-positive metastatic breast cancer at five clinical sites affiliated with Mount Sinai, NYU Langone Health, and Columbia University. Researchers first established the appropriate palbociclib dose before assessing the full four-drug regimen in 29 participants. In many treatment settings, HER2-targeted therapy is paired with chemotherapy because the combination can produce rapid and substantial tumor control. However, chemotherapy can cause fatigue, hair loss, nausea, neuropathy, suppression of the bone marrow, infection risk, and other short- and long-term complications. The ASPIRE investigators designed the study around the question of whether simultaneous control of hormonal signaling, HER2 activity, and cell-cycle progression could achieve meaningful disease control without exposing patients to chemotherapy at the outset.
The results were notable for the proportion of patients who experienced early disease control. Ninety-seven percent of participants achieved clinical benefit during the first six months of treatment, a measure that includes tumor shrinkage or prolonged disease stability. The median progression-free survival was nearly 25 months, meaning that half of the patients remained alive without documented worsening of their cancer for at least that length of time. Median overall survival had not been reached when the analysis was conducted, indicating that more than half of the participants were still alive at the time researchers evaluated the data. After a median follow-up of approximately 39 months, nearly 93 percent of patients remained alive. Several participants experienced especially durable responses, including one patient who continued receiving the regimen for more than six years.
The biological logic behind the combination is based on attacking the cancer from complementary directions rather than relying on a single dominant pathway. HER2 signaling can activate networks that promote cell growth, metabolism, invasion, and resistance to treatment. Trastuzumab and pertuzumab interfere with HER2 signaling at the cell surface, but cancer cells may use downstream pathways or alternative mechanisms to continue dividing. Endocrine therapy addresses the separate hormonal dependence of HR-positive disease, while palbociclib targets a key intracellular checkpoint that can remain active even when external growth signals are blocked. In theory, this layered inhibition may make it more difficult for tumor cells to bypass treatment. The strategy also reflects a broader movement in oncology toward molecularly coordinated regimens that are tailored to the signaling architecture of a tumor rather than built around chemotherapy as the universal backbone.
The safety findings were consistent with the known effects of the four medicines. Neutropenia, a reduction in neutrophils that can increase susceptibility to infection, was among the most common complications, along with low white blood cell counts, diarrhea, and anemia. Palbociclib is known to suppress bone marrow activity, while pertuzumab may contribute to gastrointestinal side effects such as diarrhea. Trastuzumab and pertuzumab can also require monitoring of cardiac function because HER2 signaling plays a role in the health of heart muscle cells. Despite these potential risks, only one patient discontinued treatment because of adverse effects, and no treatment-related deaths occurred. The investigators describe the overall safety profile as manageable, though larger studies will be needed to identify less common complications and determine how tolerability compares directly with chemotherapy-containing regimens.
For patients, the treatment format may be as important as the biological activity of the drugs. Anastrozole and palbociclib are administered orally, while trastuzumab and pertuzumab may be delivered by injection under the skin in appropriate settings, reducing the need for repeated intravenous chemotherapy infusions. A less intensive regimen could be particularly relevant for older adults, people living with other medical conditions, or patients whose health makes chemotherapy more difficult to tolerate. Avoiding chemotherapy may also reduce cumulative neuropathy, severe nausea, prolonged fatigue, and other effects that can interfere with work, mobility, and daily activities. Still, chemotherapy-free does not mean side-effect-free. Patients receiving this combination would require regular blood tests, medication monitoring, assessment of treatment adherence, evaluation for diarrhea and infection, and ongoing surveillance of cardiac function and cancer response.
Amy Tiersten, senior author of the study and Professor of Medicine and Clinical Director of Breast Medical Oncology at Mount Sinai, said the findings indicate that a chemotherapy-free approach can produce durable responses while maintaining a manageable safety profile for many patients. Rima Patel, the study’s first author and an Assistant Professor of Medicine at Mount Sinai, emphasized that the central challenge is balancing tumor control with quality of life. Their comments reflect the cautious interpretation appropriate for an early-phase trial: the results are encouraging, but they do not establish that the four-drug regimen is superior to existing first-line treatments. The study included only 29 patients in the treatment evaluation, and its single-arm design means that outcomes cannot be separated confidently from differences in patient characteristics, follow-up, or other factors that would be controlled in a randomized comparison.
The researchers therefore characterize the findings as hypothesis-generating and say that larger randomized clinical trials are needed. Such studies would ideally compare the ASPIRE regimen with accepted HER2-targeted treatments that include chemotherapy, while examining progression-free survival, overall survival, quality of life, patient-reported symptoms, and treatment discontinuation. They would also help determine which patients are most likely to benefit. Tumor burden, the presence or absence of visceral disease, prior exposure to endocrine therapy, genomic features, age, comorbidities, and the biological intensity of HER2 and hormone receptor signaling could all influence outcomes. It will also be important to establish whether chemotherapy can safely be omitted for all patients in this subtype or whether a chemotherapy-free strategy is best reserved for carefully selected individuals with particular clinical or molecular characteristics.
The ASPIRE study was funded in part by the National Institutes of Health through the Mount Sinai Tisch Cancer Center Support Grant, with Pfizer providing palbociclib and funding for the clinical trial. The findings were published in the Journal of the National Cancer Institute. While the results do not yet change treatment guidelines, they add to growing evidence that metastatic breast cancer care may become increasingly adaptable, with therapy chosen according to tumor biology, patient health, and personal priorities. For people with HR-positive, HER2-positive metastatic disease, the possibility of controlling cancer with a coordinated combination of targeted and endocrine treatments—without chemotherapy at the beginning—could represent a meaningful shift if future randomized studies confirm the benefit.
Subject of Research: People
Article Title: A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE)
News Publication Date: August 20, 2026
Web References: https://doi.org/10.1093/jnci/djag256
References: JNCI Journal of the National Cancer Institute; DOI: 10.1093/jnci/djag256; article published July 30, 2026
Keywords: Breast cancer, metastatic breast cancer, HER2-positive breast cancer, hormone receptor-positive breast cancer, chemotherapy-free treatment, targeted therapy, endocrine therapy, palbociclib, trastuzumab, pertuzumab, anastrozole, ASPIRE clinical trial, cancer treatment, oncology
